GlassScriptPhysician profile
R Sam Lingamfelter
NPI 1225044084
$4,536.93
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $666 · 2021: $851 · 2022: $907.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $888.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $538.87 | 2019-2022 | |
| Pfizer INC. | $423.38 | 2019-2022 | |
| Lilly USA, LLC | $417.52 | 2019-2022 | |
| Amgen INC. | $416.91 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $307.02 | 2019-2022 | |
| Eisai INC. | $285.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $187.13 | 2019-2022 | |
| Abbvie INC. | $137.22 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.81 | 2019-2021 | |
| Shire North American Group INC | $73.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.93 | 2019-2022 | |
| Allergan, INC. | $71.29 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.99 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $50.76 | 2019 | |
| Sanofi Pasteur INC. | $36.11 | 2019 | |
| Genentech USA, INC. | $30.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $29.51 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $24.88 | 2021 | |
| Ibsa Pharma INC. | $24.27 | 2021-2022 | |
| Antares Pharma, INC. | $21.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.72 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.86 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.68 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.39 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.69 | 2022 | |
| Cranial Technologies, INC | $12.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw R Sam Lingamfelter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.